Cardiovascular Diabetology

Papers
(The TQCC of Cardiovascular Diabetology is 17. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)
ArticleCitations
Persistent clotting protein pathology in Long COVID/Post-Acute Sequelae of COVID-19 (PASC) is accompanied by increased levels of antiplasmin282
Triglyceride-glucose index as a marker in cardiovascular diseases: landscape and limitations186
The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin165
Triglyceride-glucose index predicts adverse cardiovascular events in patients with diabetes and acute coronary syndrome165
Triglyceride–glucose index and the incidence of atherosclerotic cardiovascular diseases: a meta-analysis of cohort studies156
Associations between abdominal obesity indices and diabetic complications: Chinese visceral adiposity index and neck circumference133
Cardiovascular morbidity, diabetes and cancer risk among children and adolescents with severe obesity132
Prevalence of symptoms, comorbidities, fibrin amyloid microclots and platelet pathology in individuals with Long COVID/Post-Acute Sequelae of COVID-19 (PASC)117
Glycemic variability: adverse clinical outcomes and how to improve it?113
Association of the insulin resistance marker TyG index with the severity and mortality of COVID-19113
SGLT2i: beyond the glucose-lowering effect109
Risk for cardiovascular disease associated with metabolic syndrome and its components: a 13-year prospective study in the RIVANA cohort108
CAPTURE: a multinational, cross-sectional study of cardiovascular disease prevalence in adults with type 2 diabetes across 13 countries108
GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs106
Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial100
Diabetes and Covid-19 among hospitalized patients in Saudi Arabia: a single-centre retrospective study100
The impact of triglyceride-glucose index on incident cardiovascular events during 16 years of follow-up: Tehran Lipid and Glucose Study95
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis92
Positive association between triglyceride glucose index and arterial stiffness in hypertensive patients: the China H-type Hypertension Registry Study92
Acute dapagliflozin administration exerts cardioprotective effects in rats with cardiac ischemia/reperfusion injury91
Efficacy and durability of multifactorial intervention on mortality and MACEs: a randomized clinical trial in type-2 diabetic kidney disease91
Triglyceride–glucose index is associated with the risk of myocardial infarction: an 11-year prospective study in the Kailuan cohort90
Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management90
Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction89
Impacts of triglyceride-glucose index on prognosis of patients with type 2 diabetes mellitus and non-ST-segment elevation acute coronary syndrome: results from an observational cohort study in China86
SGLT2 inhibitors and atrial fibrillation in type 2 diabetes: a systematic review with meta-analysis of 16 randomized controlled trials84
Cardiometabolic multimorbidity is associated with a worse Covid-19 prognosis than individual cardiometabolic risk factors: a multicentre retrospective study (CoViDiab II)82
Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes82
Association between triglyceride-glucose index and risk of arterial stiffness: a cohort study82
Stronger association of triglyceride glucose index than the HOMA-IR with arterial stiffness in patients with type 2 diabetes: a real-world single-centre study81
Relationship between the triglyceride-glucose index and risk of cardiovascular diseases and mortality in the general population: a systematic review and meta-analysis78
Infarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: a multicenter international registry77
Effect of empagliflozin on ectopic fat stores and myocardial energetics in type 2 diabetes: the EMPACEF study77
Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analy76
Triglyceride-glucose index and the risk of stroke and its subtypes in the general population: an 11-year follow-up75
Comprehensive elaboration of glycemic variability in diabetic macrovascular and microvascular complications75
Autophagy-dependent and -independent modulation of oxidative and organellar stress in the diabetic heart by glucose-lowering drugs69
Impact of diabetes mellitus on clinical outcomes in patients affected by Covid-1969
Triglyceride glucose index for the detection of asymptomatic coronary artery stenosis in patients with type 2 diabetes68
Glycated ACE2 receptor in diabetes: open door for SARS-COV-2 entry in cardiomyocyte67
Direct cardiac effects of SGLT2 inhibitors67
Hyperglycemia, inflammatory response and infarct size in obstructive acute myocardial infarction and MINOCA67
Change in triglyceride-glucose index predicts the risk of cardiovascular disease in the general population: a prospective cohort study67
Association of TyG index and TG/HDL-C ratio with arterial stiffness progression in a non-normotensive population65
Proteomics of fibrin amyloid microclots in long COVID/post-acute sequelae of COVID-19 (PASC) shows many entrapped pro-inflammatory molecules that may also contribute to a failed fibrinolytic system65
Type 2 diabetes and reduced exercise tolerance: a review of the literature through an integrated physiology approach65
Angiotensin II-induced upregulation of SGLT1 and 2 contributes to human microparticle‐stimulated endothelial senescence and dysfunction: protective effect of gliflozins64
Empagliflozin prevents doxorubicin-induced myocardial dysfunction64
Low-grade inflammation as a risk factor for cardiovascular events and all-cause mortality in patients with type 2 diabetes63
Impact of peroxisome proliferator-activated receptor-α on diabetic cardiomyopathy63
SGLT-2 inhibitors and cardiorenal outcomes in patients with or without type 2 diabetes: a meta-analysis of 11 CVOTs61
A high triglyceride glucose index is more closely associated with hypertension than lipid or glycemic parameters in elderly individuals: a cross-sectional survey from the Reaction Study60
The association between SGLT2 inhibitors and new-onset arrhythmias: a nationwide population-based longitudinal cohort study58
Triglyceride-glucose index is associated with in-stent restenosis in patients with acute coronary syndrome after percutaneous coronary intervention with drug-eluting stents57
Global trend of diabetes mortality attributed to vascular complications, 2000–201657
Variability of risk factors and diabetes complications56
Dual SGLT-1 and SGLT-2 inhibition improves left atrial dysfunction in HFpEF56
The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs56
MicroRNAs and long non-coding RNAs in the pathophysiological processes of diabetic cardiomyopathy: emerging biomarkers and potential therapeutics55
The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management54
Renoprotection with SGLT2 inhibitors in type 2 diabetes over a spectrum of cardiovascular and renal risk52
Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis52
Fatty liver index and development of cardiovascular disease in Koreans without pre-existing myocardial infarction and ischemic stroke: a large population-based study51
Rethinking pioglitazone as a cardioprotective agent: a new perspective on an overlooked drug51
Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention49
Autonomic nervous system activity changes in patients with hypertension and overweight: role and therapeutic implications48
The longitudinal association of remnant cholesterol with cardiovascular outcomes in patients with diabetes and pre-diabetes47
Prognostic value of triglyceride glucose (TyG) index in patients with acute decompensated heart failure46
Metformin treatment in heart failure with preserved ejection fraction: a systematic review and meta-regression analysis46
Impact of admission hyperglycemia on short and long-term prognosis in acute myocardial infarction: MINOCA versus MIOCA46
Dapagliflozin effect on endothelial dysfunction in diabetic patients with atherosclerotic disease: a randomized active-controlled trial45
High triglyceride-glucose index is associated with subclinical cerebral small vessel disease in a healthy population: a cross-sectional study45
Atherogenic index of plasma is associated with major adverse cardiovascular events in patients with type 2 diabetes mellitus45
Association between the triglyceride–glucose index and severity of coronary artery disease44
Gender difference in the association between TyG index and subclinical atherosclerosis: results from the I-Lan Longitudinal Aging Study44
Correlation of physical and cognitive impairment in diabetic and hypertensive frail older adults44
Apabetalone and hospitalization for heart failure in patients following an acute coronary syndrome: a prespecified analysis of the BETonMACE study44
Prevalence of readily detected amyloid blood clots in ‘unclotted’ Type 2 Diabetes Mellitus and COVID-19 plasma: a preliminary report44
Diabetes and restenosis43
Heart failure in type 2 diabetes: current perspectives on screening, diagnosis and management43
TyG index is positively associated with risk of CHD and coronary atherosclerosis severity among NAFLD patients42
Impact of a 2-year trial of nutritional ketosis on indices of cardiovascular disease risk in patients with type 2 diabetes41
Predictive effect of triglyceride‑glucose index on clinical events in patients with type 2 diabetes mellitus and acute myocardial infarction: results from an observational cohort study in China41
The number of risk factors not at target is associated with cardiovascular risk in a type 2 diabetic population with albuminuria in primary cardiovascular prevention. Post-hoc analysis of the NID-2 tr40
Cumulative triglyceride-glucose index is a risk for CVD: a prospective cohort study40
Triglyceride-glucose index in the prediction of adverse cardiovascular events in patients with premature coronary artery disease: a retrospective cohort study40
Triglyceride-glucose index variability and incident cardiovascular disease: a prospective cohort study40
The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors40
Discordance between the triglyceride glucose index and fasting plasma glucose or HbA1C in patients with acute coronary syndrome undergoing percutaneous coronary intervention predicts cardiovascular ev40
Empagliflozin does not change cardiac index nor systemic vascular resistance but rapidly improves left ventricular filling pressure in patients with type 2 diabetes: a randomized controlled study40
Empagliflozin attenuates cardiac microvascular ischemia/reperfusion injury through improving mitochondrial homeostasis40
Arterial stiffness is an independent predictor for risk of mortality in patients with type 2 diabetes mellitus: the REBOUND study40
Accumulation of advanced glycation end products (AGEs) is associated with the severity of aortic stenosis in patients with concomitant type 2 diabetes39
Dapagliflozin: a sodium–glucose cotransporter 2 inhibitor, attenuates angiotensin II-induced cardiac fibrotic remodeling by regulating TGFβ1/Smad signaling39
Efficacy and safety of sodium-glucose cotransporter 2 inhibitors initiation in patients with acute heart failure, with and without type 2 diabetes: a systematic review and meta-analysis39
The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect38
Empagliflozin protects the heart against ischemia/reperfusion-induced sudden cardiac death38
Triglyceride-glucose index and triglyceride to high-density lipoprotein cholesterol ratio as potential cardiovascular disease risk factors: an analysis of UK biobank data38
Issues for the management of people with diabetes and COVID-19 in ICU38
Triglyceride glucose index for the detection of the severity of coronary artery disease in different glucose metabolic states in patients with coronary heart disease: a RCSCD-TCM study in China38
Different effects of SGLT2 inhibitors according to the presence and types of heart failure in type 2 diabetic patients38
Efficacy and safety of bempedoic acid for prevention of cardiovascular events and diabetes: a systematic review and meta-analysis38
Evaluation of the long-term prognostic ability of triglyceride-glucose index for elderly acute coronary syndrome patients: a cohort study37
Association between the Mediterranean lifestyle, metabolic syndrome and mortality: a whole-country cohort in Spain37
Elevated plasma succinate levels are linked to higher cardiovascular disease risk factors in young adults37
Quantitative assessment of coronary plaque volume change related to triglyceride glucose index: The Progression of AtheRosclerotic PlAque DetermIned by Computed TomoGraphic Angiography IMaging (PARADI36
Triglyceride-glucose index and common carotid artery intima-media thickness in patients with ischemic stroke36
MicroRNAs and obesity-induced endothelial dysfunction: key paradigms in molecular therapy35
MiR-30 promotes fatty acid beta-oxidation and endothelial cell dysfunction and is a circulating biomarker of coronary microvascular dysfunction in pre-clinical models of diabetes35
The role of remnant cholesterol beyond low-density lipoprotein cholesterol in diabetes mellitus34
Predictive value of the stress hyperglycemia ratio in patients with acute ST-segment elevation myocardial infarction: insights from a multi-center observational study34
Association of the atherogenic index of plasma with cardiovascular risk beyond the traditional risk factors: a nationwide population-based cohort study33
Comparative predictive ability of visit-to-visit HbA1c variability measures for microvascular disease risk in type 2 diabetes33
SGLT-2 inhibitors and atrial fibrillation in the Food and Drug Administration adverse event reporting system33
Relationship of cumulative exposure to the triglyceride-glucose index with ischemic stroke: a 9-year prospective study in the Kailuan cohort33
A prospective randomized study comparing effects of empagliflozin to sitagliptin on cardiac fat accumulation, cardiac function, and cardiac metabolism in patients with early-stage type 2 diabetes: the33
The triglyceride-glucose index predicts ischemic heart disease risk in Koreans: a prospective study using National Health Insurance Service data33
Left atrial strain and diastolic function abnormalities in obese and type 2 diabetic adolescents and young adults33
Personalized management of dyslipidemias in patients with diabetes—it is time for a new approach (2022)33
Associations between continuous glucose monitoring-derived metrics and arterial stiffness in Japanese patients with type 2 diabetes33
Elevated levels of adiponectin associated with major adverse cardiovascular and cerebrovascular events and mortality risk in ischemic stroke32
Treating type 2 diabetes in COVID-19 patients: the potential benefits of injective therapies32
Metabolic syndrome, fatty liver, and artificial intelligence-based epicardial adipose tissue measures predict long-term risk of cardiac events: a prospective study32
Triglyceride-glucose index and the risk of heart failure: Evidence from two large cohorts and a mendelian randomization analysis32
Remnant cholesterol and the risk of cardiovascular disease in type 2 diabetes: a nationwide longitudinal cohort study32
Comparison of various insulin resistance surrogates on prognostic prediction and stratification following percutaneous coronary intervention in patients with and without type 2 diabetes mellitus32
Improvement of glycemic control and reduction of major cardiovascular events in 18 cardiovascular outcome trials: an updated meta-regression31
Association of metformin monotherapy or combined therapy with cardiovascular risks in patients with type 2 diabetes mellitus31
Depression and cardiovascular risk—association among Beck Depression Inventory, PCSK9 levels and insulin resistance31
Triglyceride-glucose index trajectory and stroke incidence in patients with hypertension: a prospective cohort study31
Association of visceral adiposity index with incident nephropathy and retinopathy: a cohort study in the diabetic population30
Hospitalization for heart failure incidence according to the transition in metabolic health and obesity status: a nationwide population-based study30
Effect of empagliflozin on ketone bodies in patients with stable chronic heart failure30
The association of hepatic steatosis and fibrosis with heart failure and mortality29
SGLT2 inhibitors and lower limb complications: an updated meta‐analysis29
Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study29
Association between physical activity level and cardiovascular risk factors in adolescents living with type 1 diabetes mellitus: a cross-sectional study29
Comparison of cardiovascular outcomes between SGLT2 inhibitors in diabetes mellitus29
PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis29
HbA1c variability predicts cardiovascular complications in type 2 diabetes regardless of being at glycemic target29
Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND29
Impact of COVID-19 pandemic and diabetes on mechanical reperfusion in patients with STEMI: insights from the ISACS STEMI COVID 19 Registry29
Insulin directly stimulates mitochondrial glucose oxidation in the heart28
Independent effects of the triglyceride-glucose index on all-cause mortality in critically ill patients with coronary heart disease: analysis of the MIMIC-III database28
Empagliflozin reduced long-term HbA1c variability and cardiovascular death: insights from the EMPA-REG OUTCOME trial28
Triglyceride-glucose index trajectory and arterial stiffness: results from Hanzhong Adolescent Hypertension Cohort Study28
Diabetes as a risk factor for incident peripheral arterial disease in women compared to men: a systematic review and meta-analysis28
Effects of GLP-1 receptor agonists and SGLT-2 inhibitors on cardiac structure and function: a narrative review of clinical evidence28
Tofogliflozin does not delay progression of carotid atherosclerosis in patients with type 2 diabetes: a prospective, randomized, open-label, parallel-group comparative study28
Expression of the SARS-CoV-2 receptorACE2 in human heart is associated with uncontrolled diabetes, obesity, and activation of the renin angiotensin system27
Diabetic phenotype and prognosis of patients with heart failure and preserved ejection fraction in a real life cohort27
SGLT2-inhibitors effects on the coronary fibrous cap thickness and MACEs in diabetic patients with inducible myocardial ischemia and multi vessels non-obstructive coronary artery stenosis27
Atherogenic index of plasma for non-diabetic, coronary artery disease patients after percutaneous coronary intervention: a prospective study of the long-term outcomes in China27
Association between abdominal obesity indices and risk of cardiovascular events in Chinese populations with type 2 diabetes: a prospective cohort study27
Prognostic value of non-alcoholic fatty liver disease for predicting cardiovascular events in patients with diabetes mellitus with suspected coronary artery disease: a prospective cohort study27
Triglyceride-glucose index linked to all-cause mortality in critically ill patients: a cohort of 3026 patients27
Optimal glucose, HbA1c, glucose-HbA1c ratio and stress-hyperglycaemia ratio cut-off values for predicting 1-year mortality in diabetic and non-diabetic acute myocardial infarction patients27
Effectiveness, safety, and major adverse limb events in atrial fibrillation patients with concomitant diabetes mellitus treated with non-vitamin K antagonist oral anticoagulants27
High fibrinogen-to-albumin ratio with type 2 diabetes mellitus is associated with poor prognosis in patients undergoing percutaneous coronary intervention: 5-year findings from a large cohort27
Sodium–glucose transporter-2 inhibitors for prevention and treatment of cardiorenal complications of type 2 diabetes27
Characterization of left ventricular myocardial sodium-glucose cotransporter 1 expression in patients with end-stage heart failure27
Advanced glycation end-products, measured as skin autofluorescence, associate with vascular stiffness in diabetic, pre-diabetic and normoglycemic individuals: a cross-sectional study27
Triglyceride-glucose index in the development of peripheral artery disease: findings from the Atherosclerosis Risk in Communities (ARIC) Study27
Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials27
Effect of sodium–glucose cotransporter 2 inhibitors on cardiac structure and function in type 2 diabetes mellitus patients with or without chronic heart failure: a meta-analysis27
Association between omentin-1 and major cardiovascular events after lower extremity endovascular revascularization in diabetic patients: a prospective cohort study27
Effect of saroglitazar 2 mg and 4 mg on glycemic control, lipid profile and cardiovascular disease risk in patients with type 2 diabetes mellitus: a 56-week, randomized, double blind, phase 3 study (P27
Correlation between the triglyceride-to-high-density lipoprotein cholesterol ratio and other unconventional lipid parameters with the risk of prediabetes and Type 2 diabetes in patients with coronary 26
Landscape of cardiometabolic risk factors in Chinese population: a narrative review26
Neuregulin-4 attenuates diabetic cardiomyopathy by regulating autophagy via the AMPK/mTOR signalling pathway26
Better cardiovascular outcomes of type 2 diabetic patients treated with GLP-1 receptor agonists versus DPP-4 inhibitors in clinical practice26
Efficacy of dulaglutide on vascular health indexes in subjects with type 2 diabetes: a randomized trial26
Association of circulating PCSK9 concentration with cardiovascular metabolic markers and outcomes in stable coronary artery disease patients with or without diabetes: a prospective, observational coho26
Interaction between smoking and diabetes in relation to subsequent risk of cardiovascular events26
Triglyceride-rich lipoprotein and LDL particle subfractions and their association with incident type 2 diabetes: the PREVEND study26
Association of fasting glucose with lifetime risk of incident heart failure: the Lifetime Risk Pooling Project26
Reappraisal on pharmacological and mechanical treatments of heart failure26
From glucose lowering agents to disease/diabetes modifying drugs: a “SIMPLE” approach for the treatment of type 2 diabetes26
Role of Canagliflozin on function of CD34+ve endothelial progenitor cells (EPC) in patients with type 2 diabetes26
Association of healthy lifestyle including a healthy sleep pattern with incident type 2 diabetes mellitus among individuals with hypertension26
The associations of hepatic steatosis and fibrosis using fatty liver index and BARD score with cardiovascular outcomes and mortality in patients with new-onset type 2 diabetes: a nationwide cohort stu26
Impact of combined training with different exercise intensities on inflammatory and lipid markers in type 2 diabetes: a secondary analysis from a 1-year randomized controlled trial26
Prognostic significance of diabetes mellitus in patients with atrial fibrillation25
Mechanisms of reduced peak oxygen consumption in subjects with uncomplicated type 2 diabetes25
Sex differences in the association of prediabetes and type 2 diabetes with microvascular complications and function: The Maastricht Study25
Circulating levels of AGEs and soluble RAGE isoforms are associated with all-cause mortality and development of cardiovascular complications in type 2 diabetes: a retrospective cohort study25
High triglyceride-glucose index in young adulthood is associated with incident cardiovascular disease and mortality in later life: insight from the CARDIA study25
Cholesterol lowering therapies and achievement of targets for primary and secondary cardiovascular prevention in type 2 diabetes: unmet needs in a large population of outpatients at specialist clinics24
Clinical profiles and quality of care of subjects with type 2 diabetes according to their cardiovascular risk: an observational, retrospective study24
Risk factors for cardiovascular disease in patients with metabolic-associated fatty liver disease: a machine learning approach24
Impact of glycemic control on the association of endothelial dysfunction and coronary artery disease in patients with type 2 diabetes mellitus24
Effect of tofogliflozin on arterial stiffness in patients with type 2 diabetes: prespecified sub-analysis of the prospective, randomized, open-label, parallel-group comparative UTOPIA trial24
Glucose variability and the risks of stroke, myocardial infarction, and all-cause mortality in individuals with diabetes: retrospective cohort study24
Lipoprotein (a) predicts recurrent worse outcomes in type 2 diabetes mellitus patients with prior cardiovascular events: a prospective, observational cohort study24
Association between triglyceride glucose index and carotid artery plaque in different glucose metabolic states in patients with coronary heart disease: a RCSCD-TCM study in China24
Sex-specific differences in left ventricular mass and myocardial energetic efficiency in non-diabetic, pre-diabetic and newly diagnosed type 2 diabetic subjects24
Comparative cardiovascular safety of GLP-1 receptor agonists versus other glucose-lowering agents in real-world patients with type 2 diabetes: a nationwide population-based cohort study24
Prognostic value of fibrinogen in patients with coronary artery disease and prediabetes or diabetes following percutaneous coronary intervention: 5-year findings from a large cohort study23
Mechanisms underlying the blood pressure lowering effects of dapagliflozin, exenatide, and their combination in people with type 2 diabetes: a secondary analysis of a randomized trial23
The impact of triglyceride-glucose index on ischemic stroke: a systematic review and meta-analysis23
Association of the cumulative triglyceride-glucose index with major adverse cardiovascular events in patients with type 2 diabetes23
Peripheral arterial endothelial dysfunction predicts future cardiovascular events in diabetic patients with albuminuria: a prospective cohort study23
Association between triglyceride glucose-body mass index and cardiovascular outcomes in patients undergoing percutaneous coronary intervention: a retrospective study23
Prognostic significance of metabolomic biomarkers in patients with diabetes mellitus and coronary artery disease23
Trends in diabetes-related complications in Hong Kong, 2001–2016: a retrospective cohort study23
Non-alcoholic steatohepatitis and progression of carotid atherosclerosis in patients with type 2 diabetes: a Korean cohort study23
Impact of pitavastatin on new-onset diabetes mellitus compared to atorvastatin and rosuvastatin: a distributed network analysis of 10 real-world databases22
Association of stress induced hyperglycemia with angiographic findings and clinical outcomes in patients with ST-elevation myocardial infarction22
CCL7 as a novel inflammatory mediator in cardiovascular disease, diabetes mellitus, and kidney disease22
A molecular signature for the metabolic syndrome by urine metabolomics22
Association between triglyceride glucose index, coronary artery calcification and multivessel coronary disease in Chinese patients with acute coronary syndrome22
Association of glycated hemoglobin A1c levels with cardiovascular outcomes in the general population: results from the BiomarCaRE (Biomarker for Cardiovascular Risk Assessment in Europe) consortium22
Generalizability of sodium-glucose co-transporter-2 inhibitors cardiovascular outcome trials to the type 2 diabetes population: a systematic review and meta-analysis22
Heterogeneity of antidiabetic treatment effect on the risk of major adverse cardiovascular events in type 2 diabetes: a systematic review and meta-analysis22
Insights into SGLT2 inhibitor treatment of diabetic cardiomyopathy: focus on the mechanisms22
Visit-to-visit HbA1c variability is associated with in-stent restenosis in patients with type 2 diabetes after percutaneous coronary intervention21
Estimated glucose disposal rate and risk of stroke and mortality in type 2 diabetes: a nationwide cohort study21
Sex, age, type of diabetes and incidence of atrial fibrillation in patients with diabetes mellitus: a nationwide analysis21
Association of stress hyperglycemia ratio and in-hospital mortality in patients with coronary artery disease: insights from a large cohort study21
High pericoronary adipose tissue attenuation on computed tomography angiography predicts cardiovascular events in patients with type 2 diabetes mellitus: post-hoc analysis from a prospective cohort st21
Glycemic control and atrial fibrillation: an intricate relationship, yet under investigation21
Growth differentiation factor-15 is associated with cardiovascular outcomes in patients with coronary artery disease21
Plasma metabolomic profiling in subclinical atherosclerosis: the Diabetes Heart Study21
Cardiovascular complications in a diabetes prediction model using machine learning: a systematic review21
Distinct non-ischemic myocardial late gadolinium enhancement lesions in patients with type 2 diabetes21
Cumulative burden of metabolic syndrome and its components on the risk of atrial fibrillation: a nationwide population-based study21
The prediction of Metabolic Syndrome alterations is improved by combining waist circumference and handgrip strength measurements compared to either alone21
Impact of red cell distribution width and red cell distribution width/albumin ratio on all-cause mortality in patients with type 2 diabetes and foot ulcers: a retrospective cohort study21
Impact of diabetes mellitus on mortality in patients with acute heart failure: a prospective cohort study20
High neutrophil to lymphocyte ratio with type 2 diabetes mellitus predicts poor prognosis in patients undergoing percutaneous coronary intervention: a large-scale cohort study20
Cardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetes20
Reduction of estimated fluid volumes following initiation of empagliflozin in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the placebo-controlled, randomized EMBLE20
Serum alkaline phosphatase levels and the risk of new-onset diabetes in hypertensive adults20
Major adverse cardiovascular and limb events in patients with diabetes and concomitant peripheral artery disease treated with sodium glucose cotransporter 2 inhibitor versus dipeptidyl peptidase-4 inh20
GLP-1 mediated diuresis and natriuresis are blunted in heart failure and restored by selective afferent renal denervation20
Association of sleep disturbance with risk of cardiovascular disease and all-cause mortality in patients with new-onset type 2 diabetes: data from the Korean NHIS-HEALS20
Omega-3 polyunsaturated fatty acid supplementation versus placebo on vascular health, glycaemic control, and metabolic parameters in people with type 1 diabetes: a randomised controlled preliminary tr20
Prognostic value of soluble suppression of tumorigenesis-2 (sST2) for cardiovascular events in coronary artery disease patients with and without diabetes mellitus20
Exposure-weighted scoring for metabolic syndrome and the risk of myocardial infarction and stroke: a nationwide population-based study20
Positive association between the ratio of triglycerides to high-density lipoprotein cholesterol and diabetes incidence in Korean adults20
Metabolic syndrome and the plasma proteome: from association to causation20
Performance of the recommended ESC/EASD cardiovascular risk stratification model in comparison to SCORE and NT-proBNP as a single biomarker for risk prediction in type 2 diabetes mellitus20
Associations of (pre)diabetes with right ventricular and atrial structure and function: the Maastricht Study20
Dapagliflozin improves myocardial flow reserve in patients with type 2 diabetes: the DAPAHEART Trial: a preliminary report20
Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney19
Hypofibrinolysis in type 2 diabetes and its clinical implications: from mechanisms to pharmacological modulation19
Sodium-glucose cotransporter 2 inhibitor versus metformin as first-line therapy in patients with type 2 diabetes mellitus: a multi-institution database study19
High variability in bodyweight is associated with an increased risk of atrial fibrillation in patients with type 2 diabetes mellitus: a nationwide cohort study19
Angiogenic content of microparticles in patients with diabetes and coronary artery disease predicts networks of endothelial dysfunction19
Pericardial fat and its influence on cardiac diastolic function19
0.07534384727478